Changes in US stocks | Pharmaceutical stocks continue to rise, and AstraZeneca (AZN.US) rose more than 6% after the results

The Zhitong Finance App learned that on Friday, US pharmaceutical stocks continued to rise. Lilly (LLY.US) rose more than 4%, and AstraZeneca (AZN.US) jumped higher. As of press release, it had risen by more than 6%, with a cumulative increase of more than 15% in October. According to the news, AstraZeneca announced results for the third quarter of 2026. In terms of fixed exchange rate (CER), total revenue for the quarter increased 7% year over year to US$16.209 billion, product sales of US$15.066 billion increased 5%, and alliance revenue of US$1,107 billion increased 36%. Core earnings per share were $2.79, up 19% year over year; reported earnings per share were $2.02, up 26%. According to MarketBeat's summary forecast, the market originally expected core earnings per share of the quarter to be 2.60 US dollars and revenue of 16.0 billion US dollars, which were actually about 7% and 1% higher, respectively.

Structurally, the oncology business continued to take the lead in growth: revenue of US$7.765 billion, up 17% year on year, accounting for 48% of total revenue, of which Imfinzi grew 26% to US$1,990 billion, Enhertu (including alliance revenue) grew 35% to US$1,581 billion, and Tagrisso grew 12% to US$2,087 billion.